Equity Overview
Price & Market Data
Price: $0.83
Daily Change: +$0.0724 / 8.72%
Range: $0.734 - $0.895
Market Cap: $8,529,290
Volume: 980,009
Performance Metrics
1 Week: -13.56%
1 Month: -80.79%
3 Months: -71.86%
6 Months: -72.59%
1 Year: -52.42%
YTD: -65.43%
Company Details
Employees: 19
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United States
Details
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.